Investor Presentaiton

Soluble CD28 attenuates anti-PD-1 effect in cancer PD-1 therapy is uniquely sensitive to CD28-B7 axis activation (T-cell - APCs) CD80/CD86 APC PD-L1 CD28 鱼 PD-1 SHP-2 T cell IFNg (pg/mL) sCD28 (pg/mL) 25000 20000 15000 10000 5000 Soluble CD28 attenuates anti-PD-1 effect in cancer PBMC ○ Naive SEB SEB + CD28 SEB + SEB + Keytruda Keytruda + SCD28 H&N Cancer donor #9 * P<0.05, unpaired student T.test Compared to MK3475 treatment Soluble CD28 dynamics relates with response to PD-1 pathway therapy 12000 CR PD 8000 4000 ○ IFNg (pg/mL) 16000 PR PD 12000 8000 4000 0 BIOND BIOLOGICS Activation inhibition Kamphorst AO, Science, 2017; Hui E, Science, 2017 16 18 26 30 34 37 41 45 48 42 46 50 54 58 62 Time from first dosage of anti-PD1 therapy (weeks) Urothelial carcinoma donor treated with Nivolumab 0126 10 13 15 19 22 26 28 33 35 39 Time from first dosage of anti-PD1 therapy (weeks) Melanoma donor treated with Nivolumab CR- Complete response: PR - Partial response,: PD - progressive disease Biond Biologics Corporate Presentation | May 2021 | Non-confidential 19 涯

View entire presentation